文献速递炎症性肠病消化道肿瘤与早癌消化内镜

内镜下不可见低级别异型增生溃疡性结肠炎患者的手术与监测比较:成本效果分析

Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis.
PubMed 文献 · Gastrointest Endosc · 2017-09-04

该研究采用马尔可夫模型,在20年时间框架内评估结肠镜监测与结肠切除术对溃疡性结肠炎内镜下不可见低级别异型增生的临床与成本效果。结果显示,无合并症者自65岁起监测可推荐;年轻且术后生活质量典型者,结肠切除可能更有效且更具成本效果。结果对监测下结直肠癌发病率和术后生活质量敏感。

要点

  • 无合并症者自65岁起监测具有成本效果,可推荐监测。
  • 年轻且术后生活质量典型者,结肠切除可能更有效且更具成本效果。
  • 结果对监测下结直肠癌发病率和术后生活质量敏感。

核心结论

  • 无合并症者自65岁起可推荐监测;但年轻且术后生活质量典型的患者,结肠切除可能临床更有效且更具成本效果。

研究设计与样本

  • 采用马尔可夫模型,在20年时间框架内评估监测与手术的成本和健康结局。
  • 评估结局为获得的生命年和质量调整生命年(QALYs)。
  • 建模队列为25至75岁患者,纳入经验证的手术风险计算器估计值,并考虑心力衰竭和阻塞性气道疾病两种关键合并症的无、1种或2种情况。

主要发现

  • 与手术相比,监测在无合并症者中自61岁起、1种合并症者中自51岁起、2种合并症者中自25岁起与更多生命年和QALYs相关。
  • 在英国国家卫生与临床优化研究所当前每QALY 25,800美元阈值下,持续监测在无合并症者65岁时、有1种或以上合并症者60岁时具有成本效果。

关键数值与推荐

  • 英国国家卫生与临床优化研究所当前阈值为每QALY 25,800美元。

临床怎么用

  • 无合并症者自65岁起可推荐监测。
  • 年轻且术后生活质量典型的患者,结肠切除可能临床更有效且更具成本效果。

局限性

  • 结果对监测下结直肠癌发病率和术后生活质量敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: There is uncertainty regarding the optimal management of endoscopically invisible (flat) low-grade dysplasia in ulcerative colitis. Such a finding does not currently provide an automatic indication for colectomy; however, a recommendation of surveillance instead of surgery is controversial. The aim of this study was to determine the clinical and cost-effectiveness of colonoscopic surveillance versus colectomy for endoscopically invisible low-grade dysplasia of the colon in ulcerative colitis. METHODS: A Markov model was used to evaluate the costs and health outcomes of surveillance and surgery over a 20-year timeframe. Outcomes evaluated were life years gained and quality-adjusted life years (QALYs). Cohorts of patients aged 25 to 75 were modeled, including estimates from a validated surgical risk calculator and considering none, 1, or both of 2 key comorbidities: heart failure and obstructive airway disease. RESULTS: Surveillance is associated with more life years and QALYs compared with surgery from age 61 for those with no comorbidities, age 51 for those with 1 comorbidity and age 25 for those with 2 comorbidities. At the current United Kingdom National Institute for Health and Care Excellence threshold of $25,800 per QALY, ongoing surveillance was cost-effective at age 65 in those without comorbidities and at age 60 in those with either 1 or more comorbidities. CONCLUSIONS: Surveillance can be recommended from age 65 for those with no comorbidities; however, in younger patients with typical postsurgical quality of life, colectomy may be more effective clinically and more cost-effective. The results were sensitive to the colorectal cancer incidence rate in patients under surveillance and to quality of life after surgery.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Parker B, Buchanan J, Wordsworth S, et al. Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis. Gastrointest Endosc. 2017. PMID: 28882578. doi:10.1016/j.gie.2017.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。